News
-
Feb. 10, 2023EnPlusOne Biosciences Expands Scientific Advisory Board with Dr. Jonathan Watts, Ph.D.
EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today announced that Jonathan K. Watts, Ph.D., Professor, RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, has been appointed to the company’s Scientific Advisory Board. Dr. Watts, who was also a member of the Board of Directors of the Oligonucleotide Therapeutics Society (OTS) from 2015 to 2021, is a highly regarded scientific investigator in the oligonucleotide field. His expertise will provide meaningful contributions as EnPlusOne continues to develop and scale its proprietary enzymatic RNA (ezRNA™) synthesis platform enabling next-generation solutions for emerging RNA therapeutics.
-
Dec. 19, 2022Wyss Institute at Harvard University partners with Northpond Labs to launch RNA solutions company EnPlusOne Biosciences
Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and EnPlusOne Biosciences (EnPlusOne Bio) announced that the startup company has signed a worldwide, exclusive licensing agreement with Harvard’s Office of Technology Development (OTD) that grants EnPlusOne Bio the rights to commercialize a novel, controlled enzymatic RNA oligonucleotide synthesis technology. The “ezRNA” platform technology was invented and advanced by Wyss Core Faculty member George Church, Ph.D. and an expert team of biologists, chemists, and life science entrepreneurs at the Wyss Institute, and supported and funded by Northpond Labs, the research and development-focused affiliate of Northpond Ventures, as the inaugural project of the Wyss Institute Northpond Labs alliance.
-
Sep. 30, 2022
EnPlusOne Biosciences Launches Enzymatic RNA Synthesis Platform with $12 Million in Seed Financing
EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today formally launched with $12 million in seed financing. The round was led by Northpond Ventures with participation from Breakout Ventures, Coatue, and angel investors. The financing will support continued development and scaling of the company’s proprietary ezRNA™ synthesis platform in line with the company’s mission to enable next-generation solutions for emerging RNA therapeutics.
-
Sep. 01, 2022Daniel Wiegand on the RNA Revolution
We’re in the midst of an RNA revolution, and Daniel Wiegand and his team are prepared to deliver RNA to the world by making high-quality RNA oligonucleotides cheaper and more easily accessible. After an impactful co-op experience at a pharmaceutical company during his undergraduate years, Daniel understood what it truly meant to be a scientist, and he was hooked. His passion for cutting-edge, impactful science brought him to the Wyss, where he is leading the development of a manufacturing platform for the enzymatic synthesis of RNA oligonucleotides for use in therapeutics. Learn more about Daniel and his work in this month’s Humans of the Wyss.